Compare Amazon.com Inc (AMZN) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs BioNTech SE - ADR — how do they compare? Amazon.com Inc trades at $244.9 (market cap $2.64T), while BioNTech SE - ADR trades at $90.89 (market cap $23.14B). The key difference: Amazon.com Inc is far larger — about 114.1× BioNTech SE - ADR's market cap, and Amazon.com Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| AMZN | BNTX | |
|---|---|---|
Market Cap | $2.64T | $23.14B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $274.95 | $119.34 |
52-Week Low | $198.79 | $83.89 |
Enterprise Value | $2.71T | $6.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $245.34, down 0.69% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Recent CEO communications highlight Amazon's AI chip business reaching $20+ billion run-rate and strong visibility into future cash flows from massive capital investments.
Amazon presents a compelling investment case with 88% analyst buy ratings and a $320.75 consensus price target representing 31% upside. Key opportunities include AWS growth and AI leadership, while risks involve intense retail competition and the sustainability of massive capital expenditures. The stock's current valuation at 29.35 P/E appears reasonable given growth trajectory and profitability improvements.
BNTX trades at $91.49, down 1.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $1.14 billion for 2025, with revenue of $2.87 billion, and is undergoing a strategic shift toward oncology, including a $1 billion share buyback and manufacturing site closures affecting 1,860 jobs. Analyst consensus is strongly bullish with a $129.67 price target.
The outlook hinges on BioNTech's transition from COVID-19 vaccine dependency to oncology pipeline success. Opportunities include a strong cash position of $16.78 billion and promising clinical data, but risks involve execution challenges, sustained losses, and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
